Alpha 2.0
Login Register
» Authors » Mary S Holubasch

Mary S Holubasch

Explore the profile of Mary S Holubasch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 217
Followers 0
Related Specialties
Neurology
Psychiatry
General Medicine
Top 10 Co-Authors
Matthew R Meyer
Kevin E Yarasheski
Tim West
Philip B Verghese
Joel B Braunstein
Kristopher M Kirmess
John H Contois
Ilana Fogelman
Randall J Bateman
Scott E Harpstrite
Published In
Mol Neurodegener
Sleep
Clin Chim Acta
Alzheimers Dement
JAMA Netw Open
Affiliations
Soon will be listed here.
Recent Articles
1.
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for...
Eastwood S, Meyer M, Kirmess K, Wente-Roth T, Irvin F, Holubasch M, et al.
Diagnostics (Basel) . 2024 Aug; 14(16). PMID: 39202226
Alzheimer's disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging modalities....
2.
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid
Meyer M, Kirmess K, Eastwood S, Wente-Roth T, Irvin F, Holubasch M, et al.
Alzheimers Dement . 2024 Mar; 20(5):3179-3192. PMID: 38491912
Background: With the availability of disease-modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid...
3.
Associations of sleep duration and daytime sleepiness with plasma amyloid beta and cognitive performance in cognitively unimpaired, middle-aged and older African Americans
Cook J, Malik A, Plante D, Norton D, Langhough Koscik R, Du L, et al.
Sleep . 2023 Nov; 47(1). PMID: 38011629
Study Objectives: Given the established racial disparities in both sleep health and dementia risk for African American populations, we assess cross-sectional and longitudinal associations of self-report sleep duration (SRSD) and...
4.
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
Hu Y, Kirmess K, Meyer M, Rabinovici G, Gatsonis C, Siegel B, et al.
JAMA Netw Open . 2022 Apr; 5(4):e228392. PMID: 35446396
Importance: The diagnostic evaluation for Alzheimer disease may be improved by a blood-based diagnostic test identifying presence of brain amyloid plaque pathology. Objective: To determine the clinical performance associated with...
5.
The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis
Kirmess K, Meyer M, Holubasch M, Knapik S, Hu Y, Jackson E, et al.
Clin Chim Acta . 2021 May; 519:267-275. PMID: 34015303
Background: There is an unmet need for an accessible, less invasive, cost-effective method to facilitate clinical trial enrollment and aid in clinical Alzheimer's disease (AD) diagnosis. APOE genotype affects the...
6.
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
West T, Kirmess K, Meyer M, Holubasch M, Knapik S, Hu Y, et al.
Mol Neurodegener . 2021 May; 16(1):30. PMID: 33933117
Background: The development of blood-based biomarker tests that are accurate and robust for Alzheimer's disease (AD) pathology have the potential to aid clinical diagnosis and facilitate enrollment in AD drug...